Inventiva S.A. ADR (IVA)

May 27, 2025, 4:00 PM EDT - 10 days ago

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

May 23, 2025, 2:30 AM EDT - 15 days ago

Inventiva reports 2025 First Quarter Financial Information¹

May 23, 2025, 2:00 AM EDT - 15 days ago

Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025

May 5, 2025, 2:30 AM EDT - 4 weeks ago

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

Apr 30, 2025, 4:00 PM EDT - 5 weeks ago

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

Apr 24, 2025, 4:01 PM EDT - 6 weeks ago

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

Apr 15, 2025, 4:00 PM EDT - 7 weeks ago

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

Apr 1, 2025, 5:00 PM EDT - 2 months ago

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Mar 27, 2025, 10:50 AM EDT - 2 months ago

Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 4:00 PM EDT - 2 months ago

Inventiva reports its 2024 full year results and provides a business update

Mar 19, 2025, 4:00 PM EDT - 2 months ago

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

Feb 26, 2025, 4:00 PM EST - 3 months ago

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Feb 20, 2025, 4:00 PM EST - 3 months ago

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Feb 10, 2025, 4:00 PM EST - 4 months ago

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Jan 29, 2025, 4:00 PM EST - 4 months ago

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

Jan 24, 2025, 4:00 PM EST - 4 months ago

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Jan 22, 2025, 4:00 PM EST - 4 months ago

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Dec 17, 2024, 4:00 PM EST - 6 months ago

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 2:30 AM EST - 6 months ago

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Dec 12, 2024, 4:00 PM EST - 6 months ago

Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024

Nov 21, 2024, 4:00 PM EST - 7 months ago

Inventiva reports 2024 Third Quarter Financial Information¹

Nov 20, 2024, 4:00 PM EST - 7 months ago

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Nov 18, 2024, 8:30 AM EST - 7 months ago

Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams

ALIT

Nov 15, 2024, 4:00 PM EST - 7 months ago

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Oct 30, 2024, 4:00 PM EDT - 7 months ago

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

Oct 21, 2024, 8:30 AM EDT - 8 months ago

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Oct 14, 2024, 1:45 PM EDT - 8 months ago

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

Oct 14, 2024, 10:48 AM EDT - 8 months ago

Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?

Oct 14, 2024, 2:35 AM EDT - 8 months ago

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

Oct 14, 2024, 2:30 AM EDT - 8 months ago

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

Sep 25, 2024, 4:00 PM EDT - 9 months ago

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

Jul 31, 2024, 4:00 PM EDT - 11 months ago

Inventiva Reports Preliminary 2024 First-Half Financial Information¹

Jul 25, 2024, 4:00 PM EDT - 11 months ago

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

Jul 18, 2024, 2:30 AM EDT - 11 months ago

Inventiva announces a €20.1 million issuance of royalty certificates

Jul 8, 2024, 2:36 PM EDT - 11 months ago

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Jul 5, 2024, 4:00 PM EDT - 1 year ago

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

Jun 21, 2024, 4:00 PM EDT - 1 year ago

Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024

May 30, 2024, 2:30 AM EDT - 1 year ago

Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

May 22, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

May 21, 2024, 4:00 PM EDT - 1 year ago

Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

May 16, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

May 13, 2024, 2:30 AM EDT - 1 year ago

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

Apr 3, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

Mar 28, 2024, 11:27 AM EDT - 1 year ago

Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 3:00 AM EDT - 1 year ago

Inventiva announces the nomination of Andre Turenne as Director

Mar 27, 2024, 4:00 PM EDT - 1 year ago

Inventiva reports its 2023 full-year results

Mar 22, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

Mar 18, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

Mar 13, 2024, 4:00 PM EDT - 1 year ago

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

Mar 7, 2024, 4:00 PM EST - 1 year ago

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed